Time’s article on the best apps for managing inflammatory bowel disease (IBD) highlights several tools designed to help users track symptoms, medications, and diet, and connect with communities for support. These apps include GI Monitor, Oshi Health, MyIBD Care, and others, offering features like personalized plans, access to telehealth, and reminders for medication adherence. Each app aims to empower patients to take control of their health and improve their quality of life through tracking and support features tailored to chronic digestive issues.
Author: Abhay Panchal
At the European Association for the Study of Diabetes meeting, Louis J. Aronne, MD, argued that obesity medications could make bariatric surgery obsolete, thanks to drugs that treat multiple metabolic conditions. Francesco Rubino, MD, countered, suggesting “metabolic” surgery will continue to play a key role, especially for long-term management of obesity and related conditions. Aronne believes future treatments will address obesity earlier, while Rubino sees surgery remaining important for certain patients. Both agree obesity management is evolving rapidly.
Highmark and US Digestive Health have reached a new contract agreement that ensures continued access for Highmark members to US Digestive Health’s gastroenterology services. This deal follows negotiations and secures in-network coverage for patients. Both organizations expressed a commitment to providing high-quality care and maintaining essential services for their shared patient base. This agreement is significant for patients seeking specialized gastrointestinal care across Pennsylvania.
The largest gastroenterology physician groups in the U.S. include Texas Digestive Disease Consultants, Gastro Health, and Connecticut GI. Texas Digestive Disease Consultants tops the list with 556 physicians, followed by Gastro Health with 475, and Connecticut GI with 312. These large groups manage a range of gastroenterology care services, from evaluations to surgeries, and are well-suited for bulk purchasing and long-term partnerships due to their size and centralized decision-making processes.
True You Weight Loss has become the first practice in the U.S. to complete 5,000 endoscopic weight loss procedures. The milestone highlights the growing popularity of minimally invasive alternatives to traditional bariatric surgery. True You offers procedures like endoscopic sleeve gastroplasty (ESG) and intragastric balloon placement. The practice emphasizes non-surgical approaches to weight loss, helping patients avoid many of the risks associated with traditional surgery while achieving significant weight reduction.
A study published on Cureus evaluated the effectiveness of an app-based digestive care management program. Participants, who were adults with chronic gastrointestinal (GI) symptoms, experienced significant improvements in their symptoms after using the app. The program included symptom tracking, personalized medical nutrition therapy, and health coaching. Results showed that 83% of participants reported better symptom management, with 61% reporting reduced symptom severity. The app demonstrated promise as a tool for improving digestive health outcomes.
Guardant Health and Exact Sciences are making significant bets on blood-based tests for colorectal cancer screening. These companies are investing heavily in advancing non-invasive blood tests that could rival or complement existing screening methods like colonoscopies or stool-based tests. The goal is to increase screening rates, especially for those hesitant about traditional methods. However, the high costs of developing and marketing these tests, coupled with questions about their accuracy and regulatory approval, make this a risky but potentially groundbreaking move in cancer diagnostics.
Viome, a health diagnostics and microbiome company, has raised $25 million in Series D funding and appointed Kal Raman as COO. The company plans to expand its diagnostics division, particularly its CancerDetect test for oral and throat cancer, which has received breakthrough device designation from the FDA. Viome also aims to develop tests for conditions like IBS and IBD. CEO Naveen Jain, Viome’s founder, has raised $200 million to date, with investors including Khosla Ventures and Salesforce’s Marc Benioff.
The updated colonoscopy guidelines, released in August 2024 by the American College of Gastroenterology (ACG) and the American Society for Gastrointestinal Endoscopy (ASGE), introduce new quality indicators like bowel preparation adequacy and sessile serrated lesion detection rate. Dr. Douglas K. Rex of Indiana University and the co-author of the new guidelines and Dr. Reid Ness of Vanderbilt University emphasize the importance of these updates.
Novo Nordisk announced promising early-stage trial results for its new weight loss pill, amycretin, which showed up to 13% body weight loss in 12 weeks, surpassing the results of its blockbuster injection Wegovy. The study suggests similar side effects to other GLP-1-based drugs like Ozempic. With rising competition from pharma giants like Eli Lilly, Novo is considering accelerating amycretin’s development. If successful, the drug could represent a major shift in obesity treatment. Stock prices for Novo Nordisk surged following the news.